Brief: Relmada Therapeutics Announces Efficacy And Safety Results From The Phase 3 Long-Term Study Of Rel-1017 In Major Depressive Disorder
20/09/2023 13:43
Sept 20 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS ANNOUNCES EFFICACY AND SAFETY RESULTS
FROM
THE PHASE 3 LONG-TERM STUDY OF REL-1017 IN MAJOR DEPRESSIVE
DISORDER
* RELMADA THERAPEUTICS INC - LONG-TERM DOSING WITH REL-1017
WAS
WELL-TOLERATED
* RELMADA THERAPEUTICS INC - NO NEW SAFETY SIGNALS WERE
DETECTED
Source text for Eikon: ID:nPn9yTl8Ya
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million